Diagnosis Index entries containing back-references to Z20.2: Contact (with) - see also Exposure (to) gonorrhea Z20.2 Exposure (to) T75.89 - see also Contact, with ICD-10-CM Diagnosis Code T75.89 Gonorrhea (acute) (chronic) A54.9 ICD-10-CM Diagnosis Code A54.9 Syphilis, syphilitic (acquired) A53.9 ICD-10-CM Diagnosis Code A53.9
2019 ICD-10-CM Diagnosis Code Z11.8 Encounter for screening for other infectious and parasitic diseases Billable/Specific Code POA Exempt Approximate Synonyms Chlamydial disease screening done Screening for chlamydia (bacterial infection) Screening for chlamydia infection done Present On Admission Z11.8 is considered exempt from POA reporting.
Gonococcal infection, unspecified. A54.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM A54.9 became effective on October 1, 2019. This is the American ICD-10-CM version of A54.9 - other international versions of ICD-10 A54.9 may differ.
Z11.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Encntr screen for infections w sexl mode of transmiss; The 2021 edition of ICD-10-CM Z11.3 became effective on October 1, 2020.
2 - Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission.
Encounter for screening for infections with a predominantly sexual mode of transmission. Z11. 3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
2: Contact with and exposure to infections with a predominantly sexual mode of transmission.
For claims for screening for syphilis in men at increased risk use the following ICD-10-CM diagnosis codes: • Z11.3 - Encounter for screening for infections with a predominantly sexual mode of transmission; and. • any of Z72.
ICD-10 code Z11. 3 for Encounter for screening for infections with a predominantly sexual mode of transmission is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
STD screening requested by patient Use diagnosis code V01. 6 for “contact with or exposure to a venereal disease.” Codes V73. 88 (screening for chlamydial disease) and V74. 5 (screening for venereal disease) may be reported based on risk factors.
Sexually transmitted chlamydial infection of other sites A56. 8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM A56. 8 became effective on October 1, 2021.
3 - Encounter for screening for infections with a predominantly sexual mode of transmission.
411, Encounter for gynecological examination (general) (routine) with abnormal findings, or Z01. 419, Encounter for gynecological examination (general) (routine) without abnormal findings, may be used as the ICD-10-CM diagnosis code for the annual exam performed by an obstetrician–gynecologist.
ICD-10 code Z11. 8 for Encounter for screening for other infectious and parasitic diseases is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
A54. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.
3 - Encounter for screening for infections with a predominantly sexual mode of transmission.
ICD-9 Code Transition: 780.79 Code R53. 83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
411, Encounter for gynecological examination (general) (routine) with abnormal findings, or Z01. 419, Encounter for gynecological examination (general) (routine) without abnormal findings, may be used as the ICD-10-CM diagnosis code for the annual exam performed by an obstetrician–gynecologist.
The 2022 edition of ICD-10-CM Z11.8 became effective on October 1, 2021.
Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00 -Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways:
Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease. Type 1 Excludes. encounter for diagnostic examination-code to sign or symptom.
A bacterial infection caused by chlamydia psittaci. Humans are infected by handling sick birds. The chlamydia cause respiratory infection manifested with fever, malaise, cough, dyspnea, sore throat, photophobia and headaches.
The 2022 edition of ICD-10-CM A74.9 became effective on October 1, 2021.
In women, infection of the reproductive system can lead to pelvic inflammatory disease, which can cause infertility or serious problems with pregnancy . Babies born to infected mothers can get eye infections and pneumonia from chlamydia.
The 2022 edition of ICD-10-CM Z11.3 became effective on October 1, 2021.
Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00 -Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways:
Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease. Type 1 Excludes. encounter for diagnostic examination-code to sign or symptom.
Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease. Acute infectious disease characterized by primary invasion of the urogenital tract.
The 2022 edition of ICD-10-CM A54.9 became effective on October 1, 2021.
You can cure gonorrhea with antibiotics prescribed by your health care provider. Correct usage of latex condoms greatly reduces, but does not eliminate, the risk of catching or spreading gonorrhea. Centers for Disease Control and Prevention. ICD-10-CM A54.9 is grouped within Diagnostic Related Group (s) (MS-DRG v38.0):
Gonorrhea does not always cause symptoms, especially in women. In men, gonorrhea can cause pain when urinating and discharge from the penis. If untreated, it can cause epididymitis, which affects the testicles and can lead to infertility.
According to ICD-10 mapping, both gonorrhea and chlamydia screening should be coded to Z11.3. However, in the ICD-10 book, chlamydia is assigned to code Z11.8, and gonorrhea is not specified. Can anyone help me determine which codes are correct? Thanks in advance!
Note: Z codes represent reasons for encounters. A corresponding procedure code must accompany a Z code if a procedure is performed. Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00-Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways:
The USPSTF found convincing evidence that available screening tests can accurately diagnose chlamydial and gonococcal infections in both women and men. Nine fair-quality studies in more than 16,000 participants indicated that screening for chlamydia and gonorrhea with NAATs is highly accurate for specimens from various anatomical sites and different collection methods for women and men. 40-48 Sensitivity of NAAT specimens collected from urogenital sites for detecting chlamydia and gonorrhea in women ranged from 72% to 100%, excluding 1 outlier study. Sensitivity among collection methods, including vaginal clinician- or self-collection or urine collection, varied little. NAATs for chlamydia and gonorrhea screening in men was highly accurate, with sensitivities ranging from 89% to 100% for urethral, meatal, and urine testing. NAATs were also highly sensitive for detecting rectal and pharyngeal gonorrhea and rectal chlamydia in men (89% to 93%); they had moderate sensitivity (69%) for detecting pharyngeal chlamydia in men. Specificity for several sites was high, ranging from 90% to 100% for both infections in men and women. Specificity was not reported for gonorrhea in women at the urethral site and in men at the urethral, rectal, or pharyngeal sites. 19
In 2012, more than 1.4 million cases of chlamydia and more than 330,000 cases of gonorrhea were reported to the Centers for Disease Control and Prevention (CDC) 1.
Chlamydial infections are 10 times more prevalent than gonococcal infections (4.7% vs. 0.4%) in women aged 18 to 26 years 2. Although most identified cases are reported, the incidence of chlamydia and gonorrhea is difficult to estimate because most infections are asymptomatic and are therefore never diagnosed.
The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection. The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.
Age is a strong predictor of risk for chlamydial and gonococcal infections, with the highest infection rates occurring in women aged 20 to 24 years, followed by females aged 15 to 19 years.
These studies found that treatment of chlamydial infection was associated with significantly lower rates of preterm delivery, early rupture of membranes, and infants with low birth weight compared with no treatment or treatment failure. 53, 54 No subsequent studies met inclusion criteria for the current USPSTF review. 19, 32
The USPSTF reviewed 4 trials and concluded that screening was associated with reduced risk of PID vs no screening. 49-52 One recent large, good-quality trial of men and women (n = 63,338) in primary care clinics found that screening for chlamydia was associated with a reduction in risk of hospital-diagnosed PID compared with usual care (relative risk, 0.6 [95% CI, 0.4-1.0]), but the absolute difference was small (0.24% vs 0.38%). No differences were seen in rates of PID or epididymitis in clinics. 52 No studies reported the association between screening and disease acquisition or transmission or between screening and clinical outcomes other than PID or epididymitis. 19